HAEMATO AG: The sales of HAEMATO AG increased in the first nine months of 2020 by 23.8 % compared to the same period of the previous year to 175.6 million EUR
DGAP-News: HAEMATO AG
/ Key word(s): Quarter Results/9 Month figures
November 23, 2020
HAEMATO AG, Berlin (ISIN: DE000A289VV1), achieved IFRS group sales of EUR 59.8 million in the third quarter of 2020 (previous year: EUR 47.8 million). For the observed period from January to September 2020, sales totaled EUR 175.6 million (previous year: EUR 141.8 million). Sales were thus 23.8 % above sales in the first nine months of 2019. EBITDA is 3.1 million euros (previous year: 1.5 million euros).
Despite the pandemic, HAEMATO AG was able to largely maintain its business processes with numerous organizational measures and to guarantee a constant supply of goods to its customers.
As one of the leading providers of specialty pharmaceuticals, the HAEMATO Group benefits from competition in the primary healthcare market. The specialization in medicines for the treatment of chronic diseases and for individual therapies leads us to expect a potential for growth in the future due to demographic development.
HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
23.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||+49 (0)30 897 30 86 70|
|Fax:||+49 (0)30 897 30 86 79|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange|
|EQS News ID:||1150031|
|End of News||DGAP News Service|